Pronutria Launches Two Clinical Trials, Secures $12.25M in Funding
February 14, 2014
Pronutria, a company developing products that use individual proteins in the human diet to treat and prevent diseases, has closed a $12.25 million financing led by Flagship Ventures. The company’s ProNutrein platform delivers single proteins orally that, through the normal digestive process, act as prodrugs releasing specific combinations of amino acids. These protein nutrients enable the dietary management of diseases including diabetes, obesity, muscle loss and diseases with impaired nutrient absorption.
The financing will fund the advancement of the ProNutrein pipeline as well as the development of additional candidates as medical foods and supplements, and, in a separate business unit, as therapeutics. Pronutria previously raised $10.8 million in Series A funding at a valuation of $33.5 million in October 2013.